Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, United States of America.
Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, United States of America; University of Oklahoma Health Sciences Center, Department of Internal Medicine, Division of Rheumatology, Immunology, and Allergy, Oklahoma City, OK, United States of America.
Clin Immunol. 2021 Jan;222:108634. doi: 10.1016/j.clim.2020.108634. Epub 2020 Nov 17.
The world is engulfed by one of the most widespread and significant public health crises in decades as COVID-19 has become among the leading causes of death internationally. The novel SARS-CoV-2 coronavirus which causes COVID-19 has unified the scientific community in search of therapeutic and preventative solutions. The top priorities at the moment are twofold: first, to repurpose already-approved pharmacologic agents or develop novel therapies to reduce the morbidity and mortality associated with the ever-spreading virus. Secondly, the scientific and larger pharmaceutical community have been tasked with the development, testing, and production of a safe and effective vaccine as a longer-term solution to prevent further spread and recurrence throughout the populace. The purpose of this article is to review the most up-to-date published data regarding both the leading pharmacological therapies undergoing clinical trials and vaccine candidates in development to stem the threat of COVID-19.
由于 COVID-19 已成为国际上主要的死亡原因之一，世界正面临着几十年来最广泛和最重大的公共卫生危机之一。导致 COVID-19 的新型 SARS-CoV-2 冠状病毒使科学界团结一致，寻求治疗和预防方法。目前的首要任务有两个：首先，重新利用已经批准的药物制剂或开发新的疗法，以降低与不断传播的病毒相关的发病率和死亡率。其次，科学和大型制药界的任务是开发、测试和生产安全有效的疫苗，作为预防病毒在人群中进一步传播和复发的长期解决方案。本文旨在回顾有关正在进行临床试验的主要药物疗法和正在开发的疫苗候选物的最新已发表数据，以遏制 COVID-19 的威胁。
